Bluejay Diagnostics

Bluejay Diagnostics Total Assets

The Total Assets of Bluejay Diagnostics (BJDX) as of Oct 27, 2026 is 7.12 M USD. In the previous year, Total Assets was 6.66 M USD — a change of 6.94% (higher).

Total Assets

7.12 MUSD

YoY

6.94%

Last updated:

Total Assets of Bluejay Diagnostics is 2025 7.12 M USD. Total Assets of Bluejay Diagnostics was 2024 6.66 M USD. It decreases by 6.94% higher compared to the previous year.

The Bluejay Diagnostics Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2019
916,518.00 USD
Jan 1, 2020
1.52 M USD
Jan 1, 2021
21.02 M USD
Jan 1, 2022
13.52 M USD
Jan 1, 2023
4.87 M USD
Jan 1, 2024
6.66 M USD
Jan 1, 2025
7.12 M USD
The Bluejay Diagnostics Total Assets history
YEARTotal AssetsYoY
7.12 MUSD+6.94%
6.66 MUSD+36.74%
4.87 MUSD-63.99%
13.52 MUSD-35.67%
21.02 MUSD+1,285.25%
1.52 MUSD+65.55%
916,518.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bluejay Diagnostics Stock analysis

What does Bluejay Diagnostics do? Bluejay Diagnostics Inc generates revenue through its Symphony System, a near-patient testing platform for disease triage and monitoring. The company's first product, the Symphony IL-6 test, provides rapid sepsis diagnostics with results in about 20 minutes, targeting healthcare providers in acute care settings. The Symphony platform processes whole blood to measure key biomarkers, leveraging non-contact centrifugal force for biomarker isolation and immunoassay preparation. This solution addresses the in vitro diagnostics market segment focused on sepsis, cardio-metabolic diseases, and cancer diagnostics. The Symphony System and its initial IL-6 test are designed for medical professionals seeking faster diagnostic decisions in critical care scenarios. Bluejay Diagnostics targets hospitals and clinics requiring rapid biomarker measurements for patient triage and treatment adjustments. The company's focus on near-patient testing differentiates its offerings within the in vitro diagnostics industry, emphasizing speed and accuracy for time-sensitive conditions. Bluejay Diagnostics Inc operates within the health care equipment and supplies sector, with its Symphony platform positioned to serve the global in vitro diagnostics devices market. The company's initial product, the Symphony IL-6 test for sepsis triage, represents a targeted solution for acute medical conditions requiring immediate diagnostic insights. The Symphony analyzer's ability to process whole blood for biomarker measurement supports its application in multiple disease areas including sepsis and cardio-metabolic conditions. Bluejay Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bluejay Diagnostics stock

Total Assets of Bluejay Diagnostics is 7.12 M USD in 2025.

Total Assets of Bluejay Diagnostics changed from 6.66 M USD to 7.12 M USD, representing a 6.94% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Bluejay Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Bluejay Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bluejay Diagnostics

All Key Metrics — Bluejay Diagnostics